OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Vaginal squamous cell carcinoma (HPV-associated): lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised2
Advanced, first line1
Other settings1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersStage I, upper vaginaRadical upper vaginectomy with pelvic lymphadenectomy, or brachytherapy with or without external beam radiotherapy.40
All comersStage II to IVAExternal beam radiotherapy to the pelvis (and groins for lower-third tumours) with concurrent weekly cisplatin, followed by brachytherapy, extrapolating from cervical cancer.93

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersRecurrent or metastatic diseaseCarboplatin and paclitaxel with or without bevacizumab; pembrolizumab for PD-L1-positive tumours (KEYNOTE-826 extrapolated); pelvic exenteration for isolated central recurrence after radiotherapy.98

Other settings

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.